Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KRAS
REST API REST API
Homo sapiens
KRAS is differentially expressed in 364 experiments: 161 organism parts: cerebellum, bone marrow, ... (159 more);, 255 disease states: normal, control, ... (253 more);, 109 cell types 505 cell lines 49 compound treatments and 89 other conditions.
Synonyms KRAS1, KRAS2
Orthologs RAS2 (Saccharomyces cerevisiae)   Kras (Mus musculus)   KRAS (Gallus gallus)   RAS1 (Saccharomyces cerevisiae)   KRAS (Bos taurus)   Kras (Rattus norvegicus)   Ras85D (Drosophila melanogaster)   O62857_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, GDP binding, GTPase activity, protein binding, cytokine-mediated signaling pathway, visual learning, epidermal growth factor receptor signaling pathway, intracellular, positive regulation of cell proliferation, membrane, intracellular protein transport, social behavior, MAPKKK cascade, insulin receptor signaling pathway, positive regulation of MAP kinase activity, blood coagulation, membrane raft, membrane fraction, GTP catabolic process, GTP binding, activation of MAPKK activity, actin cytoskeleton organization, Ras protein signal transduction, axon guidance, small GTPase mediated signal transduction, nucleotide binding, positive regulation of NF-kappaB transcription factor activity, nucleocytoplasmic transport, signal transduction, protein transport, mitochondrion, negative regulation of neuron apoptosis, positive regulation of nitric-oxide synthase activity, striated muscle cell differentiation, response to mineralocorticoid stimulus, regulation of long-term neuronal synaptic plasticity, leukocyte migration, LRR domain binding, positive regulation of Rac protein signal transduction, regulation of synaptic transmission, GABAergic, nerve growth factor receptor signaling pathway, Ral guanyl-nucleotide exchange factor activity, GMP binding, response to glucocorticoid stimulus
InterPro Term Ran_GTPase, MIRO-like, ProtSyn_GTP-bd, Small_GTPase, Small_GTP-bd_dom, Small_GTPase_ARF/SAR, Small_GTPase_Ras, Small_GTPase_Rho, Small_GTPase_Rab_type
UniProt Accession Q9UM97, Q71SP6, P01116, P78460, E5FF39
Gene-Disease Assocation BLADDER CANCER, CARDIOFACIOCUTANEOUS SYNDROME, PANCREATIC CANCER, LUNG CANCER, GASTRIC CANCER, BREAST CANCER, COSTELLO SYNDROME, GASTRIC CANCER, HEREDITARY DIFFUSE; HDGC, LEUKEMIA, ACUTE MYELOID; AML, JUVENILE MYELOMONOCYTIC LEUKEMIA; JMML, NOONAN SYNDROME 3; NS3
Search EB-eye ENSG00000133703
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-19639, E-GEOD-20081
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
DU145
2
E-GEOD-17482, E-GEOD-20089
H441
2
E-GEOD-16194, E-MTAB-62
499 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (48 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
human foreskin fibroblast
2
E-GEOD-18147, E-GEOD-18265
2
2
E-TABM-130, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-26672
monocyte
1
2
E-GEOD-22373, E-GEOD-11755, E-GEOD-5099
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (79 experiments)

Factor Value U/D Experiments
sarcoma
2
E-GEOD-2719, E-MTAB-37
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
leiomyosarcoma
2
E-MTAB-62, E-MEXP-1922
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-37
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
249 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (31 experiments)

Factor Value U/D Experiments
none
2
8
E-TABM-782, E-GEOD-2803, E-MEXP-1958, E-GEOD-412, E-GEOD-5824, ... (10 experiments)
ethanol
2
E-MEXP-2241, E-GEOD-3113
dasatinib
1
E-MEXP-1561
nickel(II) chloride hexahydrate
1
E-GEOD-6907
sapphyrin PCI-2052
1
E-GEOD-6400
no estradiol
1
E-GEOD-20081
43 more value(s).


A rna yield

studied in E-TABM-325

Factor Value U/D Experiments
58.98
1
1
E-TABM-325


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (8 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-TABM-601, E-MEXP-1838, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-9593, E-MEXP-1648, ... (49 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-7307, E-GEOD-19188 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.493 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM